Background: This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m 2 given over 90 min i.v. and l-leucovorin 200 mg/m 2 given over 120 min on day 1, followed by 5-FU 400 mg/m 2 bolus and then 2400 mg/m 2 infused over 46 h) in untreated metastatic colorectal cancer (mCRC).
Prognosis is poor for patients with metastatic colorectal cancer (mCRC) with 5-year survival rates of 11% [1] . Treatment with chemotherapy and biological agents has extended median survival to 2 years, but further progress is required [2] [3] [4] . 5-Fluorouracil (5-FU), irinotecan, oxaliplatin, capecitabine, bevacizumab and cetuximab are used in various combinations and sequences. Among the cytotoxic regimens commonly employed for previously untreated mCRC, FOLFIRI (irinotecan, infused 5-FU and leucovorin) is effective and well tolerated [5] [6] [7] .
Disruption of the vascular endothelial growth factor (VEGF)/ vascular endothelial growth factor receptor (VEGFR) axis critical for angiogenesis is a proven therapeutic strategy in mCRC; the anti-VEGF antibody bevacizumab prolongs survival when combined with chemotherapy [8] [9] [10] . However, as tumours and their supporting vasculature express several receptor tyrosine kinases (RTKs) that generally act in concert to promote cell survival, proliferation and angiogenesis, targeting multiple RTKs simultaneously is a rational therapeutic approach. Notably, platelet-derived growth factor receptors (PDGFRs) that regulate the perivascular compartment also modulate angiogenesis [11] . Preclinical models have shown encouraging activity with dual targeting of PDGFR and VEGFR activity [12] .
Sunitinib malate (SU11248; SUTENTÒ; Pfizer Inc., New York) is an oral multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, stem-cell factor receptor (KIT), FMS-like tyrosine kinase-3, colony-stimulating factor-1 receptor and glial cell line-derived neurotrophic factor receptor, demonstrating single-agent antitumour activity in preclinical models including colorectal cancer [13] [14] [15] [16] and enhanced activity when coadministered with chemotherapy [13, [17] [18] [19] [20] . By targeting multiple RTKs, sunitinib exerts direct antitumour and antiangiogenic effects. Early in vivo antiangiogenic effects of sunitinib monotherapy were demonstrated by functional imaging in an experimental colon cancer model [21] .
Sunitinib monotherapy is approved for the treatment of advanced renal cell carcinoma (RCC) and imatinib-resistant/-intolerant gastrointestinal stromal tumour (GIST) [22] . It has also demonstrated encouraging activity in pancreatic neuroendocrine tumours [23] . In a phase II study of singleagent sunitinib in pretreated mCRC, sunitinib showed limited activity [24] , similar to observations with single-agent bevacizumab for chemorefractory mCRC [9] . However, the multitargeted mechanism of action of sunitinib, its tolerability and the proven efficacy of VEGF targeting in combination with cytotoxic therapy in mCRC warranted evaluation of sunitinib plus chemotherapy in mCRC.
The primary objective of this phase I study was to determine the maximum tolerated dose (MTD) and safety/tolerability of sunitinib combined with FOLFIRI in untreated mCRC. Secondary objectives included assessment of pharmacokinetics (PK) and preliminary efficacy.
patients and methods patients Eligibility criteria included age ‡18 years; metastatic, inoperable histologically confirmed adenocarcinoma of the colon or rectum; measurable disease by RECIST [25] ; Eastern Cooperative Oncology Group performance status of one or less; >6 months since completion of adjuvant 5-FU (6oxaliplatin) treatment and adequate renal, liver and haematologic function. Exclusion criteria included prior chemotherapy for metastatic disease, prior irradiation to >25% of bone marrow, surgery or radiotherapy within 4 weeks of commencing study drug, known brain metastases, myocardial infarction or other significant coronary artery/thromboembolic disease in the past 12 months, uncontrolled hypertension and bleeding diathesis/therapeutic doses of warfarin/low-molecular-weight heparin. The study received ethical and institutional review board approvals and was conducted in accordance with International Conference on Harmonisation and Good Clinical Practice guidelines. Written informed consent was mandatory.
study design and treatments
This multicentre, open-label phase I study employed a 3 + 3 doseescalation design [26] to determine a feasible dose schedule of sunitinib plus FOLFIRI in patients with chemonaive mCRC. Patients received FOLFIRI (irinotecan 180 mg/m 2 given over 90 min i.v. and l-leucovorin 200 mg/m 2 given over 120 min on day 1, followed by 5-FU 400 mg/m 2 bolus and then 2400 mg/m 2 infused over 46 h) every 2 weeks. Sunitinib was administered orally concurrently with FOLFIRI either for 4 weeks on treatment followed by 2 weeks off (Schedule 4/2) in 6-week cycles or on a continuous daily dosing (CDD) schedule. Patients were enrolled into sequential escalating sunitinib dose cohorts on the 4/2 schedule starting at 37.5 mg/day plus FOLFIRI, with planned escalation to 50 mg/day or deescalation to 25 mg/day, depending on dose-limiting toxicities (DLTs). The sunitinib CDD schedules (starting at 37.5 mg/day, with planned deescalation to 25 mg/day if required) were evaluated once the MTD had been exceeded on the 4/2 schedule. Cohorts comprised three or more patients assessable for DLT in the first 6 weeks, expanding to six patients if one DLT occurred. Dose escalation proceeded to the subsequent cohort in the absence of DLT in three patients or one or less DLT among six patients. The MTD of sunitinib combined with FOLFIRI was the primary study end point, defined as the dose level at which zero or one of six patients experienced a DLT, with two or more of three or two of six patients encountering DLTs at the next highest dose level. The MTD cohort was expanded by 12 patients and, if two or more DLTs occurred, the next lower dose level was declared the MTD. Patients not assessable for DLT for reasons other than toxicity were replaced. A delay of >4 weeks in sunitinib administration mandated patient removal from the study.
In the first six patients per group, during the first three FOLFIRI (+sunitinib) cycles, DLTs were defined as grade 4 neutropenia lasting ‡7 days, febrile neutropenia, neutropenic infection, grade ‡3 thrombocytopenia with bleeding, grade 4 thrombocytopenia lasting ‡7 days, any grade 3/4 non-haematologic toxicity lasting ‡7 days (except skin/hair discolouration, alopecia, hyperamylasemia, hyperlipasemia or asymptomatic hyperuricemia), or nausea/vomiting/diarrhoea persisting at grade 3/4 despite optimal medical therapy. Sunitinib dose reductions were permitted for DLTs and serious adverse events (SAEs) attributed to sunitinib. FOLFIRI-related haematologic adverse events (AEs) and grade 3/4 diarrhoea incurred a 20% dose reduction of 5-FU and irinotecan reduction to 150 mg/m 2 . Re-treatment required an absolute neutrophil count ‡1500/ll and platelets ‡100 000/ll. Table 2) . With the CDD schedules at 37.5 and 25 mg/day, the median number of cycles started was 4 and 5, respectively.
DLT and MTD
No DLTs occurred in the first six patients treated in the 37.5 mg/day Schedule 4/2 cohort. The MTD was exceeded at 50 mg/day on Schedule 4/2, with two of six patients experiencing DLTs (febrile neutropenia and grade 4 neutropenia lasting ‡7 days, respectively). The 37.5 mg/day Schedule 4/2 cohort was expanded by 15 patients, 2 of whom experienced febrile neutropenia during the first 6 weeks. With the 37.5 mg/day CDD schedule, DLTs were observed in two of three patients [grade 4 neutropenia lasting ‡7 days and grade 4 neutropenia lasting ‡7 days with grade 3 deep vein thrombosis (DVT), respectively]. At the lower dose of 25 mg/day on the CDD schedule, two DLTs (both grade 4 -neutropenia lasting ‡7 days) occurred among seven patients. The MTD of sunitinib combined with FOLFIRI was exceeded on both doses of the CDD schedule and was 37.5 mg/day on Schedule 4/2.
safety
The most common haematologic grade ‡3 AE was neutropenia. At the MTD, grade ‡3 neutropenia was observed in 47.6% of patients and in >80% of patients at all other dose levels ( Table 3) . Febrile neutropenia occurred in 2 of 21 patients at the MTD and an additional patient experienced neutropenic sepsis at this dose. Overall, 35% (13 of 37) of patients received haematopoietic growth factors [19% (4 of 21) at the MTD] after the DLT assessment period. Non-haematologic grade ‡3 AEs occurring in >10% of patients at the MTD were diarrhoea, vomiting and lethargy (3 of 21 patients each). Hair de-pigmentation was observed in one patient on the 25 mg/day CDD schedule (Table 3) ; skin discolouration was reported in three patients on the 4/2 schedule and two patients on the CDD schedule. Oedema (generalised or peripheral) occurred in three patients on the 4/2 schedule. Hypertension occurred in one patient at each dose level (grade 1/2, except for one grade 3 case at the MTD). At the MTD, no thrombotic Neoadjuvant capecitabine plus oxaliplatin, n = 1; adjuvant capecitabine plus oxaliplatin plus bevacizumab, n = 1; adjuvant capecitabine plus FOLFOX, n = 1; adjuvant FOLFOX, n = 3; adjuvant 5-FU, n = 4; adjuvant bevacizumab plus FOLFOX followed by adjuvant 5-FU, n = 1. 
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events were reported and epistaxis occurred in three patients (grade 1 only). No patients experienced bowel perforation and wound dehiscence occurred in one patient. Eighteen sunitinib-related SAEs occurred in 11 patients, with neutropenia and febrile neutropenia the most frequent in all patients (Appendix A2, available at Annals of Oncology online). Fourteen patients (five at the MTD) discontinued sunitinib due to AEs (Table 2) ; nine discontinuations were treatment related. At the MTD, 9 of 21 patients required sunitinib dose reductions, 13 of 21 patients required one or more sunitinib dose delays and 9 of the 23 occurrences of delay were for ‡3 weeks.
Six patients died during the follow-up period of 28 days since the last dose of study medication [disease related, n = 5; other, n = 1 (Clostridium difficile infection without neutropenia, n = 1)]. No treatment-related deaths were reported.
efficacy
The objective response rate (ORR) for sunitinib in combination with FOLFIRI at the MTD of 37.5 mg/day on schedule 4/2 was 57.9% (95% CI 33.5-79.7), including one patient with a complete response (Table 4) . There were no objective responses among patients on the 50 mg/day Schedule 4/2 or 37.5 mg/day CDD schedule. In the 25 mg/day CDD group, two of seven patients achieved a partial response (PR). The ORR for all assessable patients was 37.1% (13 of 35; 95% CI 21.5-55.1) and disease control was observed in 34 of 35 assessable patients. Three patients with PRs underwent radical resection (liver resection, n = 2; lung metastasectomy, n = 1).
pharmacokinetics Non-compartmental plasma PK parameters for sunitinib, SU12662, total drug (sunitinib + SU12662), irinotecan, 5-FU and SN-38 are summarised in Figure 1 and Appendices A3-A6 (available at Annals of Oncology online). For all sunitinib doses combined on Schedule 4/2, geometric mean ratios (sunitinib + FOLFIRI to sunitinib alone) for maximum concentration (C max ) and area under the plasma concentrationtime curve (AUC) from time 0 to 24 h (AUC 24 ), respectively, were 1.01 and 0.99 for sunitinib and 1.04 and 1.03 for total drug (sunitinib + SU12662; Appendix A3, available at Annals of Oncology online). Geometric mean ratios for irinotecan C max and AUC from time 0 to N (AUC inf ; sunitinib + FOLFIRI to FOLFIRI alone) were 1.34 and 1.28, respectively, and 0.96 and 1.35, respectively, for SN-38 C max and AUC 24 . Geometric mean ratios for 5-FU concentration at steady state (C ss ) and clearance at steady state (CL ss ; sunitinib + FOLFIRI to FOLFIRI alone) were 1.25 and 0.79, respectively. original articles
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Following intermittent dosing of sunitinib on Schedule 4/2, mean dose-corrected C trough values (day 1 of cycles 5, 8, and 11) for sunitinib, SU12662 and total drug were within the ranges of 39.0-44.4, 8.26-9.64, and 47.3-54.0 ng/ml, respectively (Appendix A4, available at Annals of Oncology online).
Due to the low tolerability of FOLFIRI + sunitinib 37.5 mg/ day on the CDD schedule, only one paired observation was available for PK evaluations. For the sunitinib 25 and 37.5 mg/ day doses combined on the CDD schedule, the geometric mean ratios (sunitinib + FOLFIRI to sunitinib alone) of C max and AUC 24 were, respectively, 1.13 and 1.06 for sunitinib, 0.83 and 1.11 for SU12662 and 1.11 and 1.03 for total drug (Appendix A5, available at Annals of Oncology online). Geometric mean ratios for irinotecan C max and AUC inf (sunitinib + FOLFIRI to FOLFIRI alone) were 1.01 and 1.23, respectively, and 0.83 and 1.11, respectively, for SN-38 C max and AUC 24 . Geometric mean ratios for 5-FU C ss and CL ss (sunitinib + FOLFIRI to FOLFIRI alone) were 1.33 and 0.74, respectively.
For the CDD schedule, insufficient trough PK data were available due to poor tolerability of this sunitinib dose schedule with FOLFIRI.
discussion
Simultaneous targeting of multiple RTKs including VEGFR and PDGFR was a rational investigational approach for treating Annals of Oncology original articles mCRC. In this phase I study of sunitinib combined with FOLFIRI for patients with untreated mCRC, the MTD was sunitinib 37.5 mg/day on Schedule 4/2. The MTD was exceeded at the higher sunitinib dose of 50 mg/day on Schedule 4/2 and at both sunitinib doses (37.5 and 25 mg/day) on the CDD schedule. DLTs across all dose levels were predominantly haematologic, with events of grade 4 neutropenia (n = 5) and febrile neutropenia (n = 1). Only one non-haematologic DLT (DVT) was observed. At the 50 mg/day Schedule 4/2 sunitinib dose, and on both CDD schedules, grade 3/4 neutropenia occurred in >80% of patients, compared with 48% of patients at the MTD.
In RCC, GIST and pretreated mCRC, sunitinib monotherapy (50 mg/day on Schedule 4/2) was associated with grade 3/4 neutropenia rates of <15% [24, 27, 28] . Rates of grade 3/4 neutropenia with FOLFIRI alone are 20%-30% [5] [6] [7] , suggesting that even at the MTD in this study, adding sunitinib increased myelotoxicity. Hence, regular FBC monitoring should be carried out when administering sunitinib plus FOLFIRI, with haematopoietic growth factor support used as necessary (19% of patients treated at the MTD in our study).
The intermittent Schedule 4/2 is the most commonly examined sunitinib schedule in clinical studies [24, [27] [28] [29] [30] [31] [32] , originally based on concerns regarding bone marrow and original articles Annals of Oncology adrenal toxicity with continuous dosing in preclinical models [33, 34] and possible drug accumulation [35] . However, the absence of sunitinib/metabolite accumulation in phase II studies of prolonged CDD in RCC [36] and GIST [37] and concerns regarding loss of biologic effect during the drug-free interval on Schedule 4/2 prompted further evaluation of CDD. In our study, both sunitinib doses administered on the CDD schedule plus FOLFIRI proved too toxic. Alternative intermittent regimens have been explored [38, 39] , including evaluation of irinotecan (250 mg/m 2 ) every 3 weeks plus sunitinib on schedule 2/1 in patients with solid tumours (n = 21), with two DLTs observed at the sunitinib 37.5 mg/day dose (grade 4 neutropenia and grade 3 fatigue) [40] . The sunitinib 25 mg/day schedule 2/1 dose was defined as the MTD, although the dose schedule of irinotecan was different from that used in the current study. Additionally, a small study of patients with pretreated mCRC found that sunitinib 25 mg/day on the CDD schedule could be safely combined with cetuximab/irinotecan administered every other week [41] .
The DLTs of sunitinib monotherapy up to 75 mg/day were lethargy, asthenia, and thrombocytopenia [33, 39] . In the current study, grade 3/4 lethargy at the MTD was observed in only 14% of patients and grade 3/4 thrombocytopenia was infrequent. The frequencies of anti-VEGFR-related grade 3/4 toxic effects including hypertension, thrombosis and bleeding were low and were lower than rates observed in bevacizumabtreated mCRC [8, 42] . Similarly, AEs related to PDGFR suppression (oedema) and KIT suppression (hair/skin discolouration) were infrequent. Gastrointestinal disturbance was common, with grade 3/4 diarrhoea and vomiting occurring in 14% of patients at the MTD. This frequency is greater than that observed with monotherapy in RCC and GIST [27, 28] but broadly consistent with the frequencies for FOLFIRI alone [6, 7] .
At the MTD, sunitinib plus FOLFIRI was associated with an overall acceptable safety profile, with most AEs grade 1/2 in severity. Although 43% and 57% of patients required sunitinib and FOLFIRI dose reductions, respectively; the incidence of AEs leading to permanent discontinuation (24%) was relatively low; most AEs were manageable with dose reductions, delays, and/or supportive care; and no treatment-related deaths occurred during the 28-day follow-up period. Preliminary antitumour activity was observed, with a 58% ORR at the MTD of sunitinib plus FOLFIRI. This compares favourably with ORRs observed in previous studies of chemotherapy combined with an anti-VEGF agent, albeit with the limitations of crossstudy comparisons [8, 42] .
The PK of sunitinib when co-administered with FOLFIRI did not appear to change compared with administration of sunitinib alone. Dose-corrected C trough values were similar across cycles for Schedule 4/2, indicating a lack of disproportionate accumulation of sunitinib and SU12662. Values for total drug were between 47.3 and 54.0 ng/ml, which are close to or within the target plasma concentration of 50-100 ng/ml required for receptor inhibition in preclinical models [13] [14] [15] 43] . The geometric mean ratio data for irinotecan, SN-38, and 5-FU also indicated that co-administration of sunitinib with FOLFIRI did not appear to affect the PK of either irinotecan or 5-FU. This lack of drug-drug interactions is consistent with previous observations [40] .
In summary, the MTD of sunitinib combined with FOLFIRI for untreated mCRC was 37.5 mg/day on Schedule 4/2. The predominant DLT was neutropenia. At the MTD, this combination had acceptable tolerability and showed preliminary antitumour activity with no significant drug-drug interactions observed between sunitinib and FOLFIRI. FOLFIRI was chosen as the cytotoxic platform in this study as it represents one of the several standard first-line cytotoxic treatments for mCRC (others include oxaliplatin-based combination therapy and fluoropyrimidine monotherapy). A randomised, placebo-controlled, phase III study of FOLFIRI alone versus FOLFIRI plus sunitinib 37.5 mg/day on Schedule 4/2 in patients with untreated mCRC was recently stopped at an interim analysis for futility [44] and publication of full results is pending. 
